673 related articles for article (PubMed ID: 19665452)
1. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
2. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
3. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties.
Rubbiani R; Kitanovic I; Alborzinia H; Can S; Kitanovic A; Onambele LA; Stefanopoulou M; Geldmacher Y; Sheldrick WS; Wolber G; Prokop A; Wölfl S; Ott I
J Med Chem; 2010 Dec; 53(24):8608-18. PubMed ID: 21082862
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
6. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.
Schuh E; Pflüger C; Citta A; Folda A; Rigobello MP; Bindoli A; Casini A; Mohr F
J Med Chem; 2012 Jun; 55(11):5518-28. PubMed ID: 22621714
[TBL] [Abstract][Full Text] [Related]
7. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type.
Rubbiani R; Can S; Kitanovic I; Alborzinia H; Stefanopoulou M; Kokoschka M; Mönchgesang S; Sheldrick WS; Wölfl S; Ott I
J Med Chem; 2011 Dec; 54(24):8646-57. PubMed ID: 22039997
[TBL] [Abstract][Full Text] [Related]
12. Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions.
Rigobello MP; Messori L; Marcon G; Agostina Cinellu M; Bragadin M; Folda A; Scutari G; Bindoli A
J Inorg Biochem; 2004 Oct; 98(10):1634-41. PubMed ID: 15458826
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: role of glutathione and the MKK4/JNK pathway.
Seyfried J; Wüllner U
Biochem Biophys Res Commun; 2007 Aug; 359(3):759-64. PubMed ID: 17559804
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
15. Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands.
Vergara E; Casini A; Sorrentino F; Zava O; Cerrada E; Rigobello MP; Bindoli A; Laguna M; Dyson PJ
ChemMedChem; 2010 Jan; 5(1):96-102. PubMed ID: 19937669
[TBL] [Abstract][Full Text] [Related]
16. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation.
Cox AG; Brown KK; Arner ES; Hampton MB
Biochem Pharmacol; 2008 Oct; 76(9):1097-109. PubMed ID: 18789312
[TBL] [Abstract][Full Text] [Related]
17. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
18. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells.
Rigobello MP; Folda A; Dani B; Menabò R; Scutari G; Bindoli A
Eur J Pharmacol; 2008 Mar; 582(1-3):26-34. PubMed ID: 18242600
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.
Hickey JL; Ruhayel RA; Barnard PJ; Baker MV; Berners-Price SJ; Filipovska A
J Am Chem Soc; 2008 Sep; 130(38):12570-1. PubMed ID: 18729360
[TBL] [Abstract][Full Text] [Related]
20. Anticancer profile of a series of gold(III) (2-phenyl)pyridine complexes.
Rubbiani R; Zehnder TN; Mari C; Blacque O; Venkatesan K; Gasser G
ChemMedChem; 2014 Dec; 9(12):2781-90. PubMed ID: 25377650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
